Start with the direct answer. If you have PTSD and the standard treatments have not helped — a proper course of trauma-focused therapy, an SSRI at adequate dose and duration, or both — you are not out of options, but the map of what remains is smaller and more honest than the headlines suggest. There is no approved psychedelic treatment for PTSD anywhere in the European Union. What exists is a defined set of routes: guideline psychotherapies with genuine evidence behind them, two approved medicines with moderate average effects, off-label uses with early evidence, and a small number of real clinical trials. This guide walks through all of them, with what the evidence and the European guidelines actually say — and without pretending any door is more open than it is.
One reassurance before the list. Not responding to a first treatment is the norm in PTSD care, not the exception, and both reference guidelines this page leans on — the UK's NICE guideline NG116 and Germany's S3-Leitlinie for post-traumatic stress disorder — plan explicitly for that case: a different trauma-focused therapy, a different format, medication added or switched. Nothing on this page is a recommendation of one option over another; which step fits you is a decision for you and a clinician who knows your history.
TL;DR Trauma-focused psychotherapy (trauma-focused CBT or EMDR) is the first-line PTSD treatment in the UK and German guidelines, and a second, different course after a failed first one is a standard guideline move — not a dead end. Medication is an option when you prefer it: sertraline and paroxetine are the only medicines authorised for PTSD, with moderate average effects. MDMA-assisted therapy has the strongest trial data in the psychedelic field and is still not an approved medicine anywhere in the EU — the US FDA declined approval in August 2024, and access in Europe is trials only, plus Switzerland's narrow programme. Ketamine and esketamine for PTSD are off-label with early evidence. The key to every door is the same: a written record of what you have tried.
What the options actually are
The fact box above compresses the whole landscape; here is the same list with the honest detail.
Trauma-focused psychotherapy — the first line, and the first thing to re-examine. Both reference guidelines put individual trauma-focused psychological therapy first: NICE instructs clinicians to offer adults with PTSD an individual trauma-focused CBT intervention — cognitive processing therapy, cognitive therapy for PTSD, narrative exposure therapy or prolonged exposure — and to offer EMDR (eye movement desensitisation and reprocessing), typically over 8 to 12 sessions with a trained practitioner (NICE NG116); the German S3 guideline takes the same trauma-focused line (AWMF 155-001). If a course "didn't work", the honest first question is what exactly was delivered: general supportive counselling is not trauma-focused therapy, a handful of sessions is not a course, and a therapy that stalled at stabilisation never reached the trauma work. A second course — of a different trauma-focused therapy, with a different therapist, or in a different format — is a standard guideline option, not an admission of failure. If you have genuinely completed a proper course and remain unwell, say exactly that to the next clinician: it changes what they offer you.
Medication — real, modest, and honestly labelled. The guidelines position drug treatment as an option, particularly when you prefer it to therapy or alongside it: NICE names venlafaxine or an SSRI such as sertraline, reviewed regularly (NICE NG116). Two medicines — sertraline and paroxetine — hold a marketing authorisation for PTSD; venlafaxine's use is off-label. The average effect across trials is moderate: enough to matter, not enough to promise. If a first SSRI has not helped, switching, adjusting dose and duration, or combining medication with trauma-focused therapy are all ordinary next moves for the prescriber — and antipsychotic augmentation exists as a specialist option for specific symptom pictures. What medication is not, in PTSD, is a substitute for the trauma-focused work the guidelines treat as central.
MDMA-assisted therapy — the strongest data in the field, and still not a medicine. Here is the honest version of the story the headlines mangle. MDMA-assisted therapy for PTSD produced two positive Phase 3 trials (MAPP1 in 2021, MAPP2 in 2023, both in Nature Medicine) — the strongest clinical results in the whole psychedelic field. And yet it is not an approved medicine anywhere in the EU: in August 2024 the US FDA declined approval, issuing a Complete Response Letter that cited incomplete safety-data collection, insufficient durability evidence and the blinding problem common to psychedelic trials, and asked for an additional Phase 3 study. The sponsor restructured and is planning a fresh trial; the EMA has no MDMA application under evaluation, and no European approval is imminent. In Europe, lawful access runs through clinical trials only — plus one standing exception, Switzerland's limited-medical-use programme, where a small number of authorised physicians may treat named patients when standard treatments have failed. The full evidence review, including the trial results and the FDA's reasons, is in our MDMA evidence review; anyone offering "MDMA therapy" commercially elsewhere in Europe is operating illegally.
Ketamine and esketamine — related medicines, off-label here. Ketamine is a licensed anaesthetic used off-label for depression in private clinics, and esketamine nasal spray (Spravato) is EU-approved — but for treatment-resistant depression, not PTSD (EMA EPAR). For PTSD itself the evidence is early: small studies, off-label use, no EU authorisation for the indication — anyone presenting either as an established PTSD treatment is ahead of the data. Where this matters practically: depression alongside PTSD is common, and if your low mood has separately failed to respond to two antidepressants in the current episode, the esketamine route may be open for the depression — that assessment, and the full evidence, are in our esketamine evidence review and ketamine evidence review, and the depression-side options in depression treatment isn't working: your options.
Psilocybin and the rest — trials, and few of them. No classic psychedelic is approved for PTSD anywhere, and the European PTSD trial pipeline is honestly small; the current studies, with registry numbers, are in the trials section below. Treat any clinic advertising psychedelic PTSD treatment in the EU outside a trial as a red flag.
How to work out where you are
First: what have you actually tried? Write it down, in one document: every psychological therapy, with its type (was it trauma-focused?), the number of sessions, whether the trauma itself was worked on, and why it ended; every medicine, with name, highest dose, duration at that dose, effect and side effects; any hospitalisations or crisis episodes. Old letters, prescriptions and your GP record are the raw material. This is not busywork: "adequate course, adequately delivered" is what every assessor looks for — the psychiatrist deciding on a medication change, the therapist judging what to offer next, and the trial screener checking eligibility criteria. (If you are reading this for someone else, our guide for family members covers how to help without pushing.)
Second: where are you now? Symptom screeners are conversation material, not diagnoses, but they anchor an appointment. Our eligibility check runs validated screeners privately in your browser — including the PHQ-2 for the depression that so often travels with PTSD — and, once you add your country and treatment history, tells you which of the routes on this page are realistically open to you. For PTSD itself, a clinician will use instruments like the CAPS-5 interview; there is no self-test that replaces that.
Trials as an option
For MDMA and psilocybin, trials are the only legal route to supervised treatment in almost all of Europe — and the honest news is that the current pipeline is small. As of September 2026, the picture on the registries looks like this. The most significant European MDMA study, a high-intensity inpatient programme for treatment-refractory PTSD at ARQ Centrum'45 in the Netherlands, is underway but enrolling by invitation rather than open application (NCT06954025; CTIS 2023-508229-28-00). Amsterdam UMC received authorisation in August 2026 for a Phase 2 trial of MDMA-assisted therapy for adolescents with treatment-resistant PTSD (CTIS 2024-515184-65-01). A psilocybin-assisted psychotherapy study for veterans with PTSD is registered at ARQ but not yet recruiting (NCT07792538). The earlier European Phase 2 MDMA study across six countries has completed (NCT04030169). Registries change: check ClinicalTrials.gov and the EU's CTIS register directly, and read our trials guide for how phases, placebo and consent work. The standard honest frame applies: trials are free, voluntary and ethics-supervised; screening is strict and most applicants are screened out; and some protocols require supervised tapering of serotonergic antidepressants — a decision to weigh with your clinician, never alone.
Frequently asked questions
Is MDMA therapy available in Europe?
Only in clinical trials. MDMA-assisted therapy has no EMA marketing authorisation and no national medicinal approval in any EU country, so supervised MDMA treatment outside research is not lawful — the exception is Switzerland's limited-medical-use programme, which treats a small number of named patients, is usually self-paid and carries long waitlists. As of September 2026 the main European MDMA trial (ARQ Centrum'45, Netherlands) enrols by invitation. Anyone selling MDMA therapy elsewhere in Europe is operating illegally.
Why isn't MDMA approved if the trials were positive?
Because positive trials and approval are not the same thing. The US FDA's August 2024 Complete Response Letter concluded the programme did not provide sufficiently reliable evidence: adverse-event data collection was incomplete, durability was insufficiently shown, and participants generally knew whether they had received MDMA, which can inflate the apparent effect. It asked for an additional Phase 3 trial. The EMA decides on its own timeline, but the same questions apply to the same trials — no European application is under evaluation.
Is ketamine or esketamine a treatment for PTSD?
Not an approved one. Esketamine's EU authorisation covers treatment-resistant depression; for PTSD, ketamine and esketamine are off-label with early, small-study evidence. If you also have depression that has failed two antidepressants, the esketamine route may be open for that — a distinct assessment worth making, covered in our depression options guide.
What actually works for PTSD, then?
Trauma-focused psychotherapy — trauma-focused CBT or EMDR — has the strongest guideline backing and is the first-line treatment in the UK and German guidelines. Sertraline and paroxetine are the approved medicines, with moderate average effects. If a first course of either has not helped, the guidelines' answer is a different evidence-based option delivered properly, not "nothing more can be done."
What if nothing has worked?
Say exactly that to a specialist, with your written treatment history in hand. Non-response sometimes has findable reasons — a therapy that never reached the trauma work, comorbid depression, sleep disorder or substance use pulling the floor out, a diagnosis worth revisiting. The remaining moves are a specialist reassessment, a second differently-delivered trauma-focused course, medication changes, and trials. If the question behind the question is despair, tell someone today: in an emergency call 112 or a crisis line — no planned treatment is the answer to a crisis.
Sources
- NICE NG116 — Post-traumatic stress disorder: recommendations
- AWMF 155-001 — S3-Leitlinie Posttraumatische Belastungsstörung (ADAPT)
- EMA — Spravato European Public Assessment Report (indication: treatment-resistant depression)
- Mitchell JM et al. MDMA-assisted therapy for severe PTSD (MAPP1). Nature Medicine 2021
- Mitchell JM et al. MDMA-assisted therapy for moderate to severe PTSD (MAPP2). Nature Medicine 2023
- Psychedelic Alpha — FDA publishes Lykos Therapeutics' MDMA Complete Response Letter
- ClinicalTrials.gov — NCT06954025, inpatient MDMA-assisted psychotherapy for treatment-refractory PTSD (ARQ Centrum'45)
- CTIS — the EU Clinical Trials Information System
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. It does not describe doses, preparation or session experiences, and it is not a guide to obtaining any substance. Discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number (112 in the EU) or a crisis line immediately.